Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease

[1]  T. Dawson,et al.  Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease , 2022, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Kameyama,et al.  Autopsy Validation of the Diagnostic Accuracy of 123I-Metaiodobenzylguanidine Myocardial Scintigraphy for Lewy Body Disease , 2022, Neurology.

[3]  S. Park,et al.  LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss , 2022, Cells.

[4]  Yuki Yoshioka,et al.  Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation , 2021, Nature Communications.

[5]  S. Knapp,et al.  Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2 , 2021, bioRxiv.

[6]  A. Myasnikov,et al.  Structural analysis of the full-length human LRRK2 , 2021, Cell.

[7]  Changhe Shi,et al.  Peripheral synucleinopathy in Parkinson disease with LRRK2 G2385R variants , 2021, Annals of clinical and translational neurology.

[8]  E. Tolosa,et al.  R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils , 2021, Acta Neuropathologica.

[9]  N. Murase,et al.  The identified clinical features of Parkinson's disease in homo-, heterozygous and digenic variants of PINK1 , 2020, Neurobiology of Aging.

[10]  D. Alessi,et al.  Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites , 2020, bioRxiv.

[11]  T. Gasser,et al.  Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells , 2020, Nature Communications.

[12]  Samara L. Reck-Peterson,et al.  Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction , 2020, Nature.

[13]  G. Oyama,et al.  Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan , 2020, Journal of Human Genetics.

[14]  Huanming Yang,et al.  An atlas of the protein-coding genes in the human, pig, and mouse brain , 2020, Science.

[15]  D. Alessi,et al.  Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease , 2020, Current opinion in cell biology.

[16]  E. Tolosa,et al.  LRRK2 in Parkinson disease: challenges of clinical trials , 2020, Nature Reviews Neurology.

[17]  Susan S. Taylor,et al.  The In Situ Structure of Parkinson’s Disease-Linked LRRK2 , 2019, Cell.

[18]  H. Okano,et al.  Mutations in CHCHD2 cause α-synuclein aggregation. , 2019, Human molecular genetics.

[19]  J. Trojanowski,et al.  Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease , 2019, Acta Neuropathologica Communications.

[20]  S. Pfeffer,et al.  PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins , 2019, bioRxiv.

[21]  Luwen Wang,et al.  RAB10 PHOSPHORYLATION IS A PROMINENT PATHOLOGICAL FEATURE IN ALZHEIMER’S DISEASE , 2019, Alzheimer's & Dementia.

[22]  M. Cookson,et al.  LRRK2 links genetic and sporadic Parkinson's disease. , 2019, Biochemical Society transactions.

[23]  Gregor Bieri,et al.  LRRK2 modifies α-syn pathology and spread in mouse models and human neurons , 2019, bioRxiv.

[24]  Susan S. Taylor,et al.  Crystal structure of the WD40 domain dimer of LRRK2 , 2019, Proceedings of the National Academy of Sciences.

[25]  N. Hattori,et al.  Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations , 2018, Acta neuropathologica communications.

[26]  E. Masliah,et al.  LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation , 2018, Nature Communications.

[27]  Xiaoling Liu,et al.  The Association between LRRK2 G2385R and Phenotype of Parkinson's Disease in Asian Population: A Meta-Analysis of Comparative Studies , 2018, Parkinson's disease.

[28]  Richard J Smeyne,et al.  Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo , 2018, Brain : a journal of neurology.

[29]  T. Gasser,et al.  Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils , 2017, The Biochemical journal.

[30]  M. Islam,et al.  G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain , 2018, Human molecular genetics.

[31]  Matthias Mann,et al.  Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis , 2017, eLife.

[32]  S. Schneider,et al.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature , 2017, Movement disorders : official journal of the Movement Disorder Society.

[33]  S. Chen,et al.  Fatigue correlates with LRRK2 G2385R variant in Chinese Parkinson's disease patients. , 2017, Parkinsonism & related disorders.

[34]  A. Dillman,et al.  The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2. , 2017, The Biochemical journal.

[35]  W. Seol,et al.  G2385R and I2020T Mutations Increase LRRK2 GTPase Activity , 2016, BioMed research international.

[36]  Matthias Mann,et al.  Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases , 2016, eLife.

[37]  Ying Wang,et al.  Effect of a Leucine-rich Repeat Kinase 2 Variant on Motor and Non-motor Symptoms in Chinese Parkinson’s Disease Patients , 2016, Aging and disease.

[38]  E. Gerhardt,et al.  LRRK2 Promotes Tau Accumulation, Aggregation and Release , 2015, Molecular Neurobiology.

[39]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[40]  Xiao-Guang Luo,et al.  LRRK2 G2385R variant carriers of female Parkinson’s disease are more susceptible to motor fluctuation , 2013, Journal of Neurology.

[41]  D. Mann,et al.  Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer’s disease brain , 2013, Acta neuropathologica communications.

[42]  K. Scearce-Levie,et al.  Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations , 2012, Science Translational Medicine.

[43]  M. Cookson,et al.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. , 2012, The Biochemical journal.

[44]  N. Hattori,et al.  LRRK2 I2020T mutation is associated with tau pathology. , 2012, Parkinsonism & related disorders.

[45]  Mark Ellisman,et al.  LRRK2 Parkinson disease mutations enhance its microtubule association. , 2011, Human molecular genetics.

[46]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[47]  E. Shin,et al.  The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. , 2010, Parkinsonism & related disorders.

[48]  D. Petrey,et al.  The WD40 Domain Is Required for LRRK2 Neurotoxicity , 2009, PLoS ONE.

[49]  H. Takagi,et al.  A meta-analysis of comparative studies of endovascular versus open repair for blunt thoracic aortic injury. , 2008, The Journal of thoracic and cardiovascular surgery.

[50]  J. Burgunder,et al.  LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han‐Chinese from mainland China , 2008, European journal of neurology.

[51]  P. Barone,et al.  Apoptotic mechanisms in mutant LRRK2-mediated cell death. , 2007, Human molecular genetics.

[52]  M. Farrer,et al.  Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.

[53]  N. Hattori,et al.  Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population , 2007, Neuroreport.

[54]  Cao Li,et al.  The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. , 2007, Movement disorders : official journal of the Movement Disorder Society.

[55]  M. Farrer,et al.  Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries , 2006, Movement disorders : official journal of the Movement Disorder Society.

[56]  A. R.,et al.  Review of literature , 1951, American Potato Journal.

[57]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[58]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[59]  R. Wallace.  Is this a practical approach? , 2001, Journal of the American College of Surgeons.